Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Characteristics of study population Characteristics | Total | Familial MS status | p value | First-degree relative | Second-/third-degree relative | No known family history: Vitamin D levels | 61.6 (27.0) | 65.4 (24.9) | 63.4 (25.5) | 61.1 (27.5) | 0.40

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were categorized as having no family history of MS, first-degree familial MS, or second-/third-degree familial MS.

Source: Abstract.

This study included individuals with MS from the Swedish population-based case: control study Epidemiologic Investigation of Multiple Sclerosis (EIMS) [].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Family history of multiple sclerosis and long-term outcomes

Case-control study · Journal of Neurology · 2026

Original publication title

Family history of multiple sclerosis and long-term outcomes

Anna Karin Hedström; Tomas Olsson; Lars Alfredsson

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Family history of MS did not appear to have a substantial prognostic impact on long-term disease outcomes after MS onset.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Family history is a well-established risk factor for multiple sclerosis (MS), but its influence on disease progression remains unclear. We investigated whether familial MS, including degree of relatedness, is associated with baseline characteristics and disease outcomes.

Source: Background

Abstract: What methods does the paper describe?

We included individuals with incident MS from the Swedish population-based epidemiologic investigation of multiple sclerosis study with longitudinal follow-up through the Swedish MS registry. Participants were categorized as having no family history of MS, first-degree familial MS, or second-/third-degree familial MS. Outcomes included confirmed disability worsening (CDW), progression to Expanded Disability Status Scale milestones 3 and 4, cognitive worsening measured by the symbol digit modalities test, MRI disease activity, and worsening on the Multiple Sclerosis Impact Scale-29. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox regression.

Source: Methods

Abstract: Results

Among 3,094 participants, 239 (7.7%) reported a first-degree relative with MS and 468 (15.1%) reported a second-/third-degree relative with MS. Baseline characteristics were similar across groups, although HLA: DRB1*15:01 positivity was more common among individuals with first-degree familial MS. No significant associations were observed between familial MS status and disability progression, cognitive decline, MRI disease activity, or patient-reported worsening. Compared with individuals without a known family history of MS, the HR for CDW was 1.06 (95% CI 0.89 to 1.30) among individuals with first-degree familial MS and 1.04 (95% CI 0.90 to 1.20) among those with second-/third-degree familial MS.

Source: Results

Abstract: Conclusions

Family history of MS did not appear to have a substantial prognostic impact on long-term disease outcomes after MS onset.

Source: Conclusions
Authors’ abstract

Background

Family history is a well-established risk factor for multiple sclerosis (MS), but its influence on disease progression remains unclear. We investigated whether familial MS, including degree of relatedness, is associated with baseline characteristics and disease outcomes.

Methods

We included individuals with incident MS from the Swedish population-based epidemiologic investigation of multiple sclerosis study with longitudinal follow-up through the Swedish MS registry. Participants were categorized as having no family history of MS, first-degree familial MS, or second-/third-degree familial MS. Outcomes included confirmed disability worsening (CDW), progression to Expanded Disability Status Scale milestones 3 and 4, cognitive worsening measured by the symbol digit modalities test, MRI disease activity, and worsening on the Multiple Sclerosis Impact Scale-29. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox regression.

Results

Among 3,094 participants, 239 (7.7%) reported a first-degree relative with MS and 468 (15.1%) reported a second-/third-degree relative with MS. Baseline characteristics were similar across groups, although HLA: DRB1*15:01 positivity was more common among individuals with first-degree familial MS. No significant associations were observed between familial MS status and disability progression, cognitive decline, MRI disease activity, or patient-reported worsening. Compared with individuals without a known family history of MS, the HR for CDW was 1.06 (95% CI 0.89 to 1.30) among individuals with first-degree familial MS and 1.04 (95% CI 0.90 to 1.20) among those with second-/third-degree familial MS.

Conclusions

Family history of MS did not appear to have a substantial prognostic impact on long-term disease outcomes after MS onset.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00415-026-14162-9.

Publication and source details

Original title: Family history of multiple sclerosis and long-term outcomes

Anna Karin Hedström; Tomas Olsson; Lars Alfredsson

Journal of Neurology · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100004359Vetenskapsrådet2016-023492020-019982024-02565Alfredsson Lars http://dx.doi.org/10.13039/501100006636Forskningsrådet om Hälsa, Arbetsliv och Välfärd2015-001952019-00697Hedström Anna Karin Alfredsson Lars swedish brain foundationFO2020-0077FO2024-0344Hedström Anna Karin Alfredsson Lars http://dx.doi.org/10.13039/501100006310Medicinska ForskningsrådetMargaretha af Ugglas Foundation

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:38:26.196904+00:00

DOI: 10.1007/s00415-026-14162-9 · PMC13615947